Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer.

Cancers·2022

Same author

Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells.

Frontiers in immunology·2019

Same author

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors.

Cells·2019

Same author

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.

Oncoimmunology·2018

Same author

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

BMC cancer·2018

Same author

No evidence for TSLP pathway activity in human breast cancer.

Oncoimmunology·2016

Search research articles

Related Experiment Video

Updated: May 10, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Targeting immunosuppression for cancer therapy.

Cristina Ghirelli¹, Thorsten Hagemann

¹Barts Cancer Institute, John Vane Science Centre, London, United Kingdom.

The Journal of Clinical Investigation

|June 4, 2013

Summary

Cancer immunity can be enhanced by targeting regulatory T cells (Tregs) within tumors. This approach may reduce tumor immunosuppression and activate the body's natural defenses against cancer.

Area of Science:

Immunology
Oncology
Cancer Research

Background:

Immune system failure is a known factor in cancer development and progression.
Significant preclinical and clinical research has advanced cancer immunology over the past two decades.
Despite progress, many fundamental questions regarding cancer immunity remain unanswered.

Purpose of the Study:

To investigate a novel therapeutic strategy for targeting tumor-infiltrating regulatory T cells (Tregs).
To evaluate the potential of modulating the tumor microenvironment to enhance anti-cancer immunity.
To explore the combined approach of dampening immunosuppression and activating innate anti-tumor immunity.

Main Methods:

Development of a novel method to target regulatory T cells (Tregs) within the tumor microenvironment.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8⁺ T Cells in Mice

Published on: June 12, 2021

Related Experiment Videos

Last Updated: May 10, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8⁺ T Cells in Mice

Published on: June 12, 2021

Assessment of strategies to reduce the immunosuppressive effects of Tregs in tumors.

Evaluation of methods to simultaneously activate innate immune responses against cancer.

Main Results:

The study demonstrates a novel method for targeting tumor-infiltrating Tregs.
The findings suggest that reducing the immunosuppressive tumor environment is feasible.
The research indicates that activating innate anti-tumor immunity alongside Treg targeting is effective.

Conclusions:

Targeting tumor-infiltrating Tregs represents a promising approach in cancer therapy.
Modulating the tumor microenvironment to reduce immunosuppression can enhance anti-cancer immunity.
Combining Treg inhibition with innate immune activation offers a potential strategy for effective cancer treatment.